EU agency moves forward meeting on Moderna COVID-19 vaccine
The European Union’s medicines agency says it has moved forward a meeting to consider authorizing a coronavirus vaccine made by Moderna for use in the 27-nation bloc
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The European Union’s medicines agency announced Thursday that it has moved forward a meeting to consider authorizing a coronavirus vaccine made by Moderna for use in the 27-nation bloc.
The Amsterdam-based agency which is meeting Monday to consider authorizing a vaccine made by Pfizer Inc. and German company BioNTech for use in the EU, had scheduled a meeting to discuss the Moderna vaccine on Jan. 12, but that has now been brought forward to Jan. 6.
The decision came after Moderna sent that last package of data on the vaccine needed for the agency to assess it for the EU market the EMA said.
“We have constantly revised our planning to further streamline all the procedural aspects that need to be in place for a robust scientific assessment that leads to a marketing authorization in all EU countries,” EMA Executive Director Emer Cooke said. "The number of infections is increasing across Europe and we are aware of the huge responsibility we have to get a vaccine to the market as quickly as is feasible, whilst maintaining the robustness of our scientific review.”
The EMA’s approval is valid in all 27 EU countries and once it is granted, countries can start receiving vaccines for immunization campaigns.
___
Follow AP’s pandemic coverage at:
https://apnews.com/hub/coronavirus-vaccine
https://apnews.com/hub/coronavirus-pandemic
https://apnews.com/UnderstandingtheOutbreak